⚠️ This AI-generated report synthesizes publicly available information. AI can make mistakes. Please double check information in this report.
Johnson & Johnson
Healthcare | Drug Manufacturers - General
⚡ Executive Summary
📊 The Bottom Line
Johnson & Johnson is a global healthcare giant focused on Innovative Medicine and MedTech following the Kenvue spin-off. It boasts a diversified portfolio and strong R&D, positioning it for stable performance. The company's strategic focus on high-growth segments underpins its core business quality.
⚖️ Risk vs Reward
At its current price of US$227.19, J&J trades below the average analyst target of US$252.42, indicating potential upside. While a bearish target of US$155.00 exists, the company's strong fundamentals and consistent dividend history suggest a favorable risk-reward profile for long-term investors seeking stability in healthcare.
🚀 Why JNJ Could Soar
- • Recent FDA and European Commission approvals for new treatments like Icotyde for psoriasis and AKEEGA for prostate cancer could significantly boost Innovative Medicine revenue and market share.
- • The strategic divestment of its consumer health business, Kenvue, allows J&J to focus investments and resources entirely on higher-margin pharmaceutical and medical technology segments, potentially accelerating growth.
- • Continued global market expansion, particularly in emerging markets in Africa and Asia, offers substantial opportunities for increased product adoption and sustained revenue growth over the long term.
⚠️ What Could Go Wrong
- • Intense competition from major pharmaceutical and MedTech rivals, coupled with the potential impact of patent expirations, could exert pressure on pricing and market share.
- • Ongoing and future regulatory hurdles and litigation risks, such as product liability claims, could lead to significant financial penalties and reputational damage.
- • Operational shifts, including the potential exploration of a US$20 billion-plus sale of its Orthopedics unit, Depuy Synthes, could disrupt the MedTech segment and overall company structure.
🏢 Company Overview
💰 How JNJ Makes Money
- • Johnson & Johnson researches, develops, manufactures, and sells a wide range of products in its Innovative Medicine segment, including treatments for oncology, immunology, and neuroscience.
- • The MedTech segment provides a diverse portfolio of products used in surgery, orthopedics, cardiovascular care, and vision, catering to hospitals and healthcare professionals globally.
- • Products are distributed through various channels, including retailers, wholesalers, distributors, hospitals, and directly to healthcare professionals for prescription and professional use.
Revenue Breakdown
Innovative Medicine
64.12%
Pharmaceutical products for various therapeutic areas like oncology and immunology.
MedTech
35.88%
Medical devices and technology for surgery, orthopedics, and vision.
🎯 WHY THIS MATTERS
This diversified revenue model, heavily weighted towards high-value pharmaceutical and medical technology solutions, provides resilience against market fluctuations and allows for consistent investment in innovation, supporting long-term growth and profitability.
⭐ Competitive Advantage: What Makes JNJ Special
1. Broad Diversified Portfolio & Global Reach
J&J's extensive portfolio across Innovative Medicine and MedTech, operating in over 60 countries and selling in 175, provides significant market penetration and reduces reliance on any single product or region. This global presence and broad offering enhance stability and access to diverse healthcare needs worldwide.
2. Robust Research and Development Capabilities
J&J's substantial investment in R&D continuously fuels its pipeline with innovative treatments and medical devices. This capability is critical for bringing new, high-value products to market, securing patents, and maintaining a leadership position in evolving therapeutic areas, driving future revenue streams.
3. Strong Brand Equity and Trust
With over a century of operation, Johnson & Johnson has cultivated a powerful brand synonymous with quality and trust among healthcare professionals and consumers. This established reputation facilitates market acceptance for new products, supports premium pricing, and fosters strong customer loyalty, enduring competitive pressures.
🎯 WHY THIS MATTERS
These integrated advantages — a vast global footprint, continuous innovation, and deep-seated trust — collectively reinforce Johnson & Johnson's competitive moat. They enable the company to adapt to healthcare trends, capture new opportunities, and sustain long-term market leadership despite intense industry competition.
👔 Who's Running The Show
Joaquin Duato
CEO & Chairman
Joaquin Duato joined J&J in 1989, becoming CEO in January 2022 and Chairman in January 2023. He spearheaded the Kenvue spin-off and led the pharmaceutical division's turnaround. Duato emphasizes technology and diversity, bringing over three decades of deep industry understanding and strategic leadership to the diversified healthcare company.
⚔️ What's The Competition
Johnson & Johnson operates in a highly competitive global healthcare market, facing significant rivals across its Innovative Medicine (pharmaceuticals) and MedTech (medical devices) segments. Competition stems from both large diversified conglomerates and specialized innovators, driven by R&D, pipeline strength, market share, and regulatory approvals.
📊 Market Context
- Total Addressable Market - The global healthcare market is valued at over US$9 trillion, projected to grow due to aging populations, chronic diseases, and technological advancements like AI and digital health.
- Key Trend - Artificial intelligence integration and digital health solutions are rapidly transforming diagnostics, treatment personalization, and operational efficiency across the healthcare sector.
Competitor
Description
vs JNJ
Pfizer Inc.
A leading global pharmaceutical company with a strong focus on research and development, known for its extensive portfolio in vaccines and therapeutic areas like oncology and immunology.
Competes directly with J&J's Innovative Medicine segment in key therapeutic areas, relying on its robust drug pipeline and global sales infrastructure.
Merck & Co., Inc.
Recognized for its cutting-edge treatments in oncology, particularly Keytruda, and a strong presence in vaccine development. Merck maintains substantial investments in R&D.
Challenges J&J in the pharmaceutical market, especially in cancer immunotherapy and vaccines, leveraging its research prowess and market penetration.
📊 Valuation & Analysis
📈 Wall Street Summary
Analyst Rating Distribution - 1 Strong Sell, 10 Hold, 9 Buy, 5 Strong Buy
1
10
9
5
12-Month Price Target Range
Low Target
US$155
-32%
Average Target
US$252
+11%
High Target
US$285
+25%
Closing: US$227.19 (1 May 2026)
🚀 The Bull Case - Upside to US$285
1. Strong Product Pipeline and Recent Approvals
High Probability
Successful development and recent approvals for products like Icotyde and AKEEGA signal a robust pipeline, potentially driving billions in new annual revenue and solidifying market leadership in specific disease areas.
2. Increased Focus on High-Growth Segments
High Probability
The strategic spin-off of Kenvue allows J&J to concentrate capital and talent on its Innovative Medicine and MedTech segments, which typically command higher margins and growth rates, potentially boosting overall profitability and innovation speed.
3. Global Healthcare Demand Tailwinds
High Probability
Aging populations, rising chronic disease prevalence, and expanding access to healthcare in emerging markets are structural tailwinds that will continue to drive sustained demand for J&J's products over the next decade.
🐻 The Bear Case - Downside to US$155
1. Intense Competition and Patent Cliffs
Medium Probability
The highly competitive pharmaceutical and MedTech landscapes, combined with potential patent expirations on key drugs, could lead to market share erosion and pricing pressure, impacting future revenue and profitability.
2. Regulatory and Litigation Challenges
Medium Probability
Ongoing legal battles, such as those related to product liability, and increasing regulatory scrutiny could result in significant financial outflows, legal costs, and reputational damage, affecting investor confidence.
3. Disruption from Divestitures
Medium Probability
The potential sale of a large unit like Depuy Synthes Orthopedics, while strategic, could temporarily disrupt operations, impact specific segment revenues, and alter the company's overall diversified profile in the short to medium term.
🔮 Final thought: Is this a long term relationship?
Owning Johnson & Johnson for a decade hinges on the belief in its enduring diversified healthcare model and strong R&D capabilities. Its ability to consistently innovate and adapt to regulatory landscapes will be crucial. While competition and litigation present ongoing challenges, J&J's global reach and established trust position it well. The strategic focus on Innovative Medicine and MedTech should drive long-term value, provided it continues to deliver pipeline successes and efficiently manage its portfolio for sustained growth.
📋 Appendix
Financial Performance
Metric
31 Dec 2025
31 Dec 2024
31 Dec 2023
Income Statement
Revenue
US$94.19B
US$88.82B
US$85.16B
Gross Profit
US$63.94B
US$61.35B
US$58.61B
Operating Income
US$25.60B
US$21.25B
US$22.01B
Net Income
US$26.80B
US$14.07B
US$35.15B
EPS (Diluted)
11.03
5.79
13.72
Balance Sheet
Cash & Equivalents
US$19.71B
US$24.11B
US$21.86B
Total Assets
US$199.21B
US$180.10B
US$167.56B
Total Debt
US$47.93B
US$36.63B
US$29.33B
Shareholders' Equity
US$81.54B
US$71.49B
US$68.77B
Key Ratios
Gross Margin
67.9%
69.1%
68.8%
Operating Margin
27.2%
23.9%
25.8%
Return on Equity
32.87
19.68
51.11
Analyst Estimates
Metric
Annual (31 Dec 2026)
Annual (31 Dec 2027)
EPS Estimate
US$11.58
US$12.71
EPS Growth
+7.3%
+9.8%
Revenue Estimate
US$100.9B
US$107.2B
Revenue Growth
+7.1%
+6.3%
Number of Analysts
25
25
Valuation Ratios
| Metric | Value | Description |
|---|---|---|
| P/E Ratio (TTM) | 26.33 | The trailing twelve-month Price-to-Earnings ratio indicates how much investors are willing to pay for each dollar of J&J's earnings over the past year. |
| Forward P/E | 17.87 | The forward Price-to-Earnings ratio reflects investor expectations for J&J's future earnings performance over the next twelve months. |
| PEG Ratio | 2.99 | The PEG ratio assesses J&J's valuation by considering its P/E ratio in relation to its expected earnings growth, offering a more complete picture than P/E alone. |
| Price/Sales (TTM) | 5.68 | The trailing twelve-month Price-to-Sales ratio compares J&J's market capitalization to its revenue, indicating how much investors are willing to pay for each dollar of sales. |
| Price/Book (MRQ) | 6.73 | The most recent quarter's Price-to-Book ratio evaluates J&J's market value against its book value, reflecting how investors perceive its assets relative to liabilities. |
| EV/EBITDA | 16.89 | Enterprise Value to EBITDA measures J&J's total value, including debt, relative to its earnings before interest, taxes, depreciation, and amortization, often used for comparing capital-intensive companies. |
| Return on Equity (TTM) | 26.42 | The trailing twelve-month Return on Equity reveals how much profit J&J generates for each dollar of shareholders' equity, indicating its efficiency in using equity to generate profits. |
| Operating Margin | 27.41 | The operating margin shows how much profit J&J makes from each dollar of revenue after covering operating costs, illustrating its operational efficiency. |
Peer Comparison
| Company | Market Cap (B) | P/E Ratio | P/B Ratio | Revenue Growth (%) | Operating Margin (%) |
|---|---|---|---|---|---|
| Johnson & Johnson (Target) | 546.90 | 26.33 | 6.73 | 9.9% | 27.4% |
| Pfizer Inc. | 149.77 | 19.36 | 1.73 | -4.3% | 30.6% |
| Merck & Co., Inc. | 277.02 | 31.59 | 5.28 | 4.9% | 41.2% |
| Sector Average | — | 25.48 | 3.51 | 0.3% | 35.9% |